Phase III results with Gocovri in Parkinson's disease published in Movement Disorders Clinical Practice.- Adamas Pharmaceuticals.
Adamas Pharmaceuticals announced that subgroup analyses of Parkinson's disease patients taking amantadine immediate release (IR) who were still experiencing dyskinesia and enrolled into EASE LID 2, the long-term, ongoing Phase III open-label study of Gocovri (amantadine) extended release capsules, were published online in Movement Disorders Clinical Practice.
Results from the subgroup analysis showed that the 32 Parkinson's disease patients who were taking amantadine IR at enrollment experienced a 35 percent improvement in motor complications at Week 8, the first post-baseline visit, after transitioning directly to Gocovri, without exacerbating adverse events. The effects were maintained for the 64-week period assessed. The safety and tolerability profile of these patients was consistent with prior controlled studies.
See: "Parkinson's patients with dyskinesia switched from immediate release amantadine to open-label ADS-5102" Stuart H. Isaacson et al, Movement Disorders Clinical Practice online: 5 FEB 2018 03:45AM EST | DOI: 10.1002/mdc3.12595
Comment: Comment: Levodopa is a standard treatment for Parkinsons disease but comes with severe side effects (levodopa induced dyskinesia) that worsen with continued exposure to the drug that is estimated to affect some 15% of Parkinsons patients. Gocovri is a high dose 274 mg amantadine (equivalent to 340 mg amantadine HCl) taken once-daily at bedtime that delivers consistently high levels of amantadine from the morning and throughout the day when dyskinesia occurs.
Related news and insights
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced that Health Canada has approved Ferriprox (deferiprone) for the treatment of iron overload in patients with sickle cell disease (SCD) or other anemias.
The Menarini Group and Radius Health announced positive topline results from the phase III EMERALD study evaluating RAD 1901 (elacestrant) as a monotherapy versus the standard of care (SoC) for the treatment of ER+/HER2- advanced or metastatic breast cancer (mBC).
Gilead Sciences, Inc. announced the FDA approved a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy.